Who is sponsoring NCT05268172?

NCT05268172 is sponsored by Affiliated Hospital of Jiangnan University.

What drugs are being tested in NCT05268172?

Interventions in NCT05268172: IFN-γ and CIK cells, Tcm cells or CAR T cells.

What condition does NCT05268172 study?

NCT05268172 studies Pleural Effusion, Malignant.

Is NCT05268172 still recruiting?

NCT05268172 is currently recruiting now. Last updated 16 May 2024.

Last reviewed 2024-05-16 · How we verify

NCT05268172

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

IFN-γ Combined With T Cells in the Treatment of Refractory Malignant Pleural Effusion and Ascites

Recruiting now Phase 1 Last updated 16 May 2024

What this trial tests

Phase 1 trial testing IFN-γ and CIK cells, Tcm cells or CAR T cells in Pleural Effusion, Malignant in 40 participants. Currently enrolling.

Timeline

20 December 2022

Primary endpoint
30 December 2024

30 December 2025

Quick facts

Lead sponsor	Affiliated Hospital of Jiangnan University
Phase	Phase 1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	40
Start date	20 December 2022
Primary completion	30 December 2024
Estimated completion	30 December 2025
Sites	1 location across China

Drugs / interventions tested

IFN-γ and CIK cells, Tcm cells or CAR T cells — full drug profile →

Conditions studied

Pleural Effusion, Malignant — all drugs for Pleural Effusion, Malignant →

Sponsor

Affiliated Hospital of Jiangnan University

Who can join

18 and older, any sex, with Pleural Effusion, Malignant. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study was to evaluate the efficacy of IFN- Y combined with T cells in the treatment of refractory malignant pleural effusion and acties, using a multicenter, single-arm, open design.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Type 1 and type 2 cytokine-mediated immune orchestration in the tumour microenvironment and their therapeutic potential.
Jou E. · · 2023 · cited 13× · PMID 37455828 · DOI 10.37349/etat.2023.00146
The Tumor Environment in Peritoneal Carcinomatosis and Malignant Pleural Effusions: Implications for Therapy.
Mirsky PO, Wagner PL, Mandic-Popov M, Donnenberg VS, et al · · 2025 · cited 1× · PMID 41097743 · DOI 10.3390/cancers17193217
Clinical trial landscape of CAR-based cell therapy for gastrointestinal malignancies.
Li W, Yang J, Kong Q, Chen Z. · · 2026 · PMID 41807034 · DOI 10.1136/jitc-2025-014286

Verify or expand the search:

Other recruiting trials for Pleural Effusion, Malignant

Currently open trials in the same condition.

NCT06946498 — First Local Anaesthesia Thoracoscopy for Pleural Effusion Diagnosis. · NA · recruiting
NCT06512896 — Clinical Study on Intraluminal Injection of FOLactis · NA · recruiting
NCT04844827 — Pleural Carcinomatosis Tissue Banking · recruiting
NCT04684459 — Dual-targeting HER2 and PD-L1 CAR-T for Solid Tumors · EARLY_PHASE1 · recruiting

Other Affiliated Hospital of Jiangnan University trials

Trials by the same sponsor.

NCT07023861 — The Exploration of Novel Radionuclide-labeled HER2-targeting Antibodies in the Diagnosis of HER2-positive Malignancies · EARLY_PHASE1 · enrolling by invitation
NCT07023848 — PET Image Exploration of 89Zr-labeled Antibody Fragments Targeting HER2 in Patients With Malignant Tumors · EARLY_PHASE1 · enrolling by invitation
NCT07162779 — Evaluation of [68Ga]DOTA-IR-780-C-4 in PET Imaging Studies for PSMA-Positive Prostate Cancer Patients · NA · enrolling by invitation
NCT06448975 — An Exploratory Study of Deep Cervical Lymphovenous Bypass (LVB) in Alzheimer's Disease · NA · recruiting
NCT06723665 — The Exploration of 18F-PSMA-1007 PET/CT Imaging in Prostate Cancer Patients · NA · enrolling by invitation

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05268172 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Affiliated Hospital of Jiangnan University
Last refreshed: 16 May 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05268172.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing